<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00643136</url>
  </required_header>
  <id_info>
    <org_study_id>1008-000-167</org_study_id>
    <nct_id>NCT00643136</nct_id>
  </id_info>
  <brief_title>A Study of Lyrica as Treatment for Sleep Problems in Patients With Sleep Problems and Seizures</brief_title>
  <official_title>Pregabalin BID Add-on Trial: a Randomized, Double-Blind, Placebo-Controlled Parallel-Group Single-Center Sleep EEG Study in Patients With Partial Seizures and Sleep Disturbance Part B: a Randomized, Double-Blind, Placebo-Controlled Parallel-Group Study of Pregabalin Add-on Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the effects of pregabalin on sleep problems in
      patients with seizures.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2002</start_date>
  <completion_date type="Actual">June 2004</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in polysomnographic (PSG) sleep efficiency in the efficacy evaluable population</measure>
    <time_frame>Endpoint</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in total sleep time</measure>
    <time_frame>Endpoint</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in sleep onset latency</measure>
    <time_frame>Endpoint</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in wake after sleep onset</measure>
    <time_frame>Endpoint</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in percent sleep spent in stages 3 and 4</measure>
    <time_frame>Endpoint</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in percent sleep spent in REM stage</measure>
    <time_frame>Endpoint</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in night sleep quality based on Groningen Sleep Questionnaire (GSQ)</measure>
    <time_frame>Endpoint</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in 4-week sleep quality (Medical Outcomes Study [MOS] Sleep Scale)</measure>
    <time_frame>Endpoint</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events and laboratory value changes</measure>
    <time_frame>Endpoint</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">17</enrollment>
  <condition>Sleep Deprivation</condition>
  <condition>Epilepsies, Partial</condition>
  <arm_group>
    <arm_group_label>Pregabalin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pregabalin</intervention_name>
    <description>Pregabalin capsules 75 mg twice daily on Days 1-4, then 150 mg twice daily on Days 5-28</description>
    <arm_group_label>Pregabalin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching placebo capsules twice daily for 28 days</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Partial epileptic seizures

          -  Not taking more than 1 background antiepileptic drug at study entry

          -  Disturbed sleep

        Exclusion Criteria:

          -  More than 1 secondarily generalized tonic/clonic seizure per week on average over the
             previous 3 months

          -  Medical, psychological, or social conditions that could interfere with normal sleep
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Den Haag</city>
        <zip>2501 CK</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Heeze</city>
        <zip>5591 VE</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=1008-000-167&amp;StudyName=A%20study%20of%20Lyrica%20as%20treatment%20for%20sleep%20problems%20in%20patients%20with%20sleep%20problems%20and%20seizures</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>April 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 19, 2008</study_first_submitted>
  <study_first_submitted_qc>March 19, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 26, 2008</study_first_posted>
  <last_update_submitted>April 23, 2008</last_update_submitted>
  <last_update_submitted_qc>April 23, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 24, 2008</last_update_posted>
  <responsible_party>
    <name_title>Director, Clinical Trial Disclosure Group</name_title>
    <organization>Pfizer, Inc.</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Seizures</mesh_term>
    <mesh_term>Sleep Deprivation</mesh_term>
    <mesh_term>Epilepsies, Partial</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pregabalin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

